secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0000805928-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen reports preliminary Q4 revenue $59.9M (+21.3% YoY); full-year $225.2M (+20.2%); FDA BLA approval for Avance
--------------------------------------------------------------------------------

- Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).
- Gross margin expected above 74% for Q4 and FY 2025; includes ~$1.9M one-time costs related to Avance BLA approval, 67% non-cash.
- Cash, equivalents, restricted cash, and investments ~$45.5M at Dec 31, 2025, up ~$6.0M from end of 2024.
- FDA approved Biologics License Application for Avance (acellular nerve allograft) on Dec 3, 2025.
- Growth driven by commercial strategy targeting Extremities and OMF-Head & Neck, and increased Resensation penetration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000004/0000805928-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000004/axgn-20260112.htm
  HTML page:      https://secwatch.observer/filing/0000805928-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer